Approved indications: In the United States, Camzyos is approved only for adults with symptomatic New York Heart Association (NYHA) class II–III obstructive hypertrophic cardiomyopathy to improve exercise capacity and relieve symptoms such as shortness of breath, chest discomfort, and fatigue.

Off‑label uses: Mavacamten has been studied in adults with symptomatic nonobstructive hypertrophic cardiomyopathy, but large phase 3 trials did not show a clear improvement in exercise capacity or quality of life compared with placebo, so routine off‑label use for nonobstructive HCM or other heart diseases is not established and is generally confined to clinical research or highly selected specialist practice.

Efficacy expectations: In trials of adults with obstructive HCM already receiving standard therapy, many patients experienced noticeable improvements in exercise tolerance and NYHA class, together with substantial reductions in left ventricular outflow tract gradient, typically over about 8–16 weeks of dose‑titrated treatment, with benefits maintained over 30–40 weeks when left ventricular ejection fraction (LVEF) was kept at or above 50 percent.

Comparison with other therapies: Traditional medicines for obstructive HCM, such as beta‑blockers, non‑dihydropyridine calcium‑channel blockers, and disopyramide, work indirectly by slowing the heart and reducing contractility, whereas Camzyos directly targets cardiac myosin, the molecular motor driving hypercontractility; this targeted action can lessen obstruction and, in some patients, reduce or delay the need for septal reduction procedures, but it requires structured imaging follow‑up, careful attention to drug interactions, and carries a boxed warning for heart failure.

Typical dosing and how to take it: For adults with symptomatic obstructive HCM and LVEF at least 55 percent, the usual starting dose is 5 mg by mouth once daily, with allowable maintenance doses of 2.5, 5, 10, or 15 mg once daily; capsules may be taken with or without food and should always be swallowed whole, without breaking, opening, or chewing.

Special dosing instructions: The dose is individualized using symptoms and regular echocardiograms of LVEF and left ventricular outflow tract gradient, with the goal of relieving obstruction while maintaining LVEF at or above 50 percent; dose increases may be delayed, or treatment temporarily interrupted, during serious infections, new or uncontrolled arrhythmias, or other illnesses that could impair heart function, and lower starting doses or dose reductions are required when certain CYP2C19 or CYP3A4 inhibitor drugs are used.

Missed dose and overdose guidance: If a dose is missed, it should be taken as soon as possible that same day, then the next dose taken at the usual time the following day, but two doses should never be taken on the same day; if more than the prescribed amount is taken, or if severe dizziness, fainting, chest pain, or sudden worsening shortness of breath occurs after an extra dose, contact the prescribing clinician, call a poison control center, or seek emergency medical care right away.

Common side effects: The most frequently reported side effects are dizziness (in roughly one quarter of treated patients) and fainting or near‑fainting; these often occur early in therapy or after dose changes, are usually mild to moderate, and should be reported promptly if they are persistent, severe, or associated with falls.

Serious or rare adverse effects: Camzyos can reduce the heart’s pumping strength and cause heart failure, with warning signs such as new or worsening shortness of breath (especially when lying flat), rapid weight gain, swelling of the legs or ankles, chest pain, fast or irregular heartbeat, or marked fatigue; these symptoms require immediate medical attention and may lead to temporary interruption or permanent discontinuation of the drug.

Warnings and precautions: Because of the risk of heart failure due to systolic dysfunction, Camzyos has a boxed warning and is available only through the CAMZYOS REMS Program; it should not be started in patients with LVEF below 55 percent, and treatment is interrupted if LVEF falls below 50 percent or clinical status worsens, with regular echocardiograms required before and during treatment. Based on animal data, Camzyos may cause fetal harm, so pregnancy should be excluded before starting, effective contraception is required during treatment and for 4 months after the last dose, and use during pregnancy is generally avoided; breastfeeding decisions are individualized because it is unknown whether mavacamten is excreted in human milk. Safety and effectiveness have not been established in children; in adults with mild to moderate hepatic impairment or mild to severe renal impairment not on dialysis, no specific initial dose adjustment is recommended beyond the standard titration algorithm, but closer monitoring is advised, and there is limited experience in patients with severe hepatic impairment or end‑stage kidney disease on dialysis.

Overall safety compared with other drugs: Compared with older therapies for obstructive HCM, Camzyos provides targeted benefits but has distinctive risks of reduced LVEF and clinically important interactions with many other medicines, so it is typically prescribed and monitored by cardiologists familiar with the REMS requirements.

Reporting side effects and finding safety updates: Patients in the United States can report suspected side effects to the FDA MedWatch program or to Bristol Myers Squibb, and the most current safety information is provided in the Medication Guide, full Prescribing Information, and on the CAMZYOS REMS and FDA websites.

Prescription drug interactions: Camzyos is mainly broken down by CYP2C19 and CYP3A4 enzymes, so taking it with strong CYP2C19 inhibitors (for example, some antifungals or antidepressants) or with moderate to strong CYP2C19 or CYP3A4 inducers (such as rifampin, carbamazepine, phenytoin, or St. John’s wort) is contraindicated because this can markedly increase the risk of heart failure or reduce effectiveness; moderate or strong CYP3A4 inhibitors and weaker CYP2C19 inhibitors can still raise Camzyos levels and usually require starting at a lower dose or dose reduction plus extra echocardiographic monitoring.

Other heart medicines and negative inotropes: Combining Camzyos with other drugs that decrease heart muscle contractility, such as disopyramide, certain calcium‑channel blockers like verapamil or diltiazem used with beta‑blockers, or other potent negative inotropes, can increase the chance of low LVEF and heart failure, so these regimens should be managed only by specialists with close supervision and imaging follow‑up.

OTC medicines, supplements, alcohol, and foods: Over‑the‑counter acid‑reducing agents that affect CYP2C19 (such as omeprazole, esomeprazole, or cimetidine), some herbal products (especially St. John’s wort), and grapefruit or grapefruit juice can alter Camzyos blood levels and should not be started, stopped, or changed without consulting the prescriber; moderate alcohol use is not specifically prohibited but should be discussed, particularly in people with liver disease or unstable heart failure.

Monitoring and precautions: Before and throughout treatment, patients need periodic echocardiograms to measure LVEF and outflow‑tract gradient as required by the CAMZYOS REMS program; clinicians may also monitor blood pressure, heart rate and rhythm, symptoms, and when appropriate, blood tests for liver and kidney function, as well as baseline and follow‑up pregnancy testing in females of reproductive potential.

Q: What is Camzyos prescribed for?
A: Camzyos is prescribed for adults with symptomatic obstructive hypertrophic cardiomyopathy (NYHA class II–III) to improve how far they can exercise and to lessen symptoms such as shortness of breath, chest pain, and fatigue.

Q: How long does it take for Camzyos to start working?
A: Many people begin to notice symptom improvement over several weeks as the dose is adjusted, with full benefits on exercise capacity and outflow‑tract obstruction often assessed over a few months of carefully monitored treatment.

Q: Will I need regular echocardiograms while taking Camzyos?
A: Yes, regular echocardiograms are required before starting and during treatment to measure your ejection fraction and outflow‑tract gradient, which guide dose adjustments and help prevent the heart from becoming too weak.

Q: Can I take Camzyos with my other heart or blood pressure medicines?
A: Some heart medicines, especially those that strongly lower heart contractility or affect CYP2C19 or CYP3A4 enzymes, can interact with Camzyos, so your cardiologist will review all your prescriptions and may adjust doses or avoid certain combinations.

Q: What happens if I become pregnant while on Camzyos?
A: Because Camzyos may harm an unborn baby, you should contact your healthcare provider right away if you become pregnant or think you might be pregnant during treatment or within 4 months after your last dose so that the medicine and pregnancy can be managed safely.

Storage: Store Camzyos capsules at room temperature 68–77°F (20–25°C), with short excursions allowed between 59 and 86°F (15–30°C), in the original tightly closed container, protected from moisture, and out of the reach of children and pets.

Disposal: When capsules are expired or no longer needed, use a pharmacy or community medicine take‑back program if available; if none is available, ask a pharmacist for local instructions, which typically include placing unused capsules (in a sealed container or bag mixed with an undesirable substance such as coffee grounds or cat litter) in household trash, and avoid flushing medicines unless specifically instructed.